The Q1 2017 EPS Estimates for CONMED Corporation Cut by Leerink Swann (CNMD), Report finds

The Q1 2017 EPS Estimates for CONMED Corporation Cut by Leerink Swann (CNMD), Report finds

Other research analysts have also recently issued research reports about the stock. Needham & Company LLC lifted their price target on shares of CONMED Corporation from $49.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, November 18th. Zacks Investment Research upgraded shares of CONMED Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, December 13th.

CONMED Corporation (NASDAQ:CNMD) – Leerink Swann reduced their Q1 2017 earnings per share estimates for shares of CONMED Corporation in a report released on Monday. Leerink Swann analyst R. Newitter now anticipates that the firm will earn $0.37 per share for the quarter, down from their previous estimate of $0.43. Leerink Swann currently has a “Neutral” rating on the stock. Leerink Swann also issued estimates for CONMED Corporation’s Q2 2017 earnings at $0.41 EPS, Q3 2017 earnings at $0.40 EPS, Q4 2017 earnings at $0.71 EPS, FY2017 earnings at $1.88 EPS and FY2018 earnings at $2.11 EPS.

CONMED Corporation (NASDAQ:CNMD) opened at 42.81 on Wednesday. The company has a market cap of $1.19 billion, a PE ratio of 82.33 and a beta of 0.77. CONMED Corporation has a 1-year low of $35.57 and a 1-year high of $50.16. The company has a 50-day moving average price of $43.89 and a 200-day moving average price of $42.04.

CONMED Corporation (NASDAQ:CNMD) last released its earnings results on Wednesday, February 1st. The medical technology company reported $0.54 EPS for the quarter, missing the Zacks’ consensus estimate of $0.56 by $0.02. The firm earned $204.10 million during the quarter, compared to the consensus estimate of $204.04 million. CONMED Corporation had a net margin of 1.92% and a return on equity of 8.38%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.52 EPS.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Teacher Retirement System of Texas boosted its position in CONMED Corporation by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 3,490 shares of the medical technology company’s stock worth $167,000 after buying an additional 429 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in CONMED Corporation by 1.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 5,730 shares of the medical technology company’s stock worth $230,000 after buying an additional 100 shares during the period. Mason Street Advisors LLC purchased a new position in CONMED Corporation during the second quarter worth $241,000. Alambic Investment Management L.P. boosted its position in CONMED Corporation by 39.2% in the third quarter. Alambic Investment Management L.P. now owns 7,100 shares of the medical technology company’s stock worth $284,000 after buying an additional 2,000 shares during the period. Finally, Aperio Group LLC boosted its position in CONMED Corporation by 33.3% in the third quarter. Aperio Group LLC now owns 7,115 shares of the medical technology company’s stock worth $285,000 after buying an additional 1,778 shares during the period.

About CONMED Corporation

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Its products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Related posts

Leave a Comment